Previous Article | Next Article ![]()
Molecular and Cellular Biology, February 2005, p. 1135-1145, Vol. 25, No. 3
0270-7306/05/$08.00+0 doi:10.1128/MCB.25.3.1135-1145.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Daniel Konrad,1,
,
Mohamed Eweida,2,
Craig Jefferies,1
Nicole Liadis,2
Adria Giacca,3
Mike Crackower,4
Akira Suzuki,5
Tak W. Mak,6
C. Ronald Kahn,7
Amira Klip,1 and
Minna Woo2,8*
Programme in Cell Biology, The Hospital for Sick Children,1 Division of Cellular and Molecular Biology, Ontario Cancer Institute,2 Department of Physiology, University of Toronto,3 Advanced Medical Discoveries Institute,6 St. Michael's Hospital, Toronto, Ontario, Canada,8 Amgen Inc., Thousand Oaks, California,4 Department of Biochemistry, Akita University School of Medicine, Akita, Japan,5 Research Division, Joslin Diabetes Center, and Department of Medicine, Harvard Medical School, Boston, Massachusetts7
Received 27 July 2004/ Returned for modification 25 August 2004/ Accepted 27 October 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
The phosphoinositide 3-kinase (PI3K)/Akt pathway is well characterized as a mediator of the receptor tyrosine kinases, including the insulin receptor. Activation of this pathway promotes a vast array of cellular processes, including cellular proliferation, differentiation, and survival (reviewed in reference 34). The biological response to the activation of the PI3K pathway is highly regulated and tissue specific (1, 21). In particular, the PI3K/Akt pathway is an important effector of insulin actions mediating glucose uptake and glycogen synthesis in muscle and fat (8, 17, 20, 48) and inhibiting glycogenolysis and glucose release from the liver (8).
Pten is a potent negative modulator of the PI3K/Akt pathway (37). In Caenorhabditis elegans, its homolog DAF-18 acts in the insulin receptor-like pathway and regulates longevity and dauer larva development (13, 27, 30). In humans, Pten was first described as a tumor suppressor (24, 39). Initial mutations were described for Cowden's syndrome, where hamartomas and increased susceptibility to cancer occur. Recently, polymorphisms of PTEN have been described in association with type 2 diabetes in a Japanese cohort (16).
Null mutation of Pten in mice leads to embryonic lethality, precluding studies of disease mechanisms (41). Tissue-specific Pten knockout models have, however, brought new insight into the biological role of Pten in different tissue and cell types (1). In proliferating or tumor-prone tissues such as the liver, endometrium, skin, prostate, or breast, Pten deletion has a permissive effect on tumor development (2, 15, 38, 42). On the other hand, Pten controls cell size in highly specialized cells such as neurons (3). Pten has also been shown to modulate highly specialized functions of a given tissue, such as class switching of immunoglobulin in B cells or metabolic actions of insulin in liver (15, 40, 43). Pten reduction in liver and fat, by systemic administration of Pten antisense oligonucleotide, protected db/db mice from developing diabetes (5). Therefore, the biological role of Pten is highly dependent on the tissue type and can range from its antiproliferative effect in tumor development to modulation of a highly specialized function for a given tissue.
Skeletal muscle is a major insulin responsive tissue, and insulin resistance in muscle is a predominant early defect in the pathogenesis of type 2 diabetes (47). However, the contribution of a defect in insulin signaling in muscle towards insulin resistance and diabetes is not entirely clear. Muscle-specific insulin receptor knockout (MIRKO) mice did not appear to display a major defect in glucose homeostasis, whereas muscle-specific deletion of GLUT4 contributes to development of insulin resistance and diabetes (4, 51). Phosphatases such as protein tyrosine phosphatase 1B (PTP-1B) and SHIP2 also play a role in the development of diabetes and obesity. The extent of their effect varies depending on the specific phosphatase, from neonatal hypoglycemia to protection from obesity (7, 9). Furthermore, the specific role of these molecules in different insulin target tissues, which results in the perturbation of whole-body fuel metabolism, is not yet known.
The aim of this study was to examine the modulatory role of Pten in insulin action in skeletal muscle and its contribution to whole-body insulin resistance and diabetes. We used the Cre-loxP system, wherein Cre expression was driven by the muscle creatine kinase (MCK) promoter (4). MCK is expressed in skeletal and cardiac muscle. In cardiac muscle, Pten has been shown to play a role in cardiac hypertrophy and contractility (10). However, the role of Pten in insulin signaling in skeletal muscle has not been examined. Here we show that deletion of muscle Pten protects mice from the development of high-fat-induced insulin resistance and diabetes. This protection continues even in aged mice, without demonstrable tumor development.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Metabolic studies. Blood glucose levels were determined from tail venous blood with an automated glucose monitor (One touch II; Lifescan, Inc., Milpitas, Calif.). Insulin and glucose tolerance tests were done on animals that had been fasted overnight. Animals were injected with either 1.5 U of human regular insulin (Eli Lilly Canada Inc., Toronto, Ontario, Canada) per kg of body weight or 1 g of glucose per kg of body weight into the peritoneal cavity. Blood glucose levels were measured immediately before and 15, 30, 45, 60, and 120 min after the injection. Insulin levels were measured from tail venous blood following an overnight fast by radioimmunoassay with rat insulin as a standard (Linco Research Inc., St. Charles, Mo.).
2-Deoxy-D-glucose uptake into isolated skeletal muscles. Intact soleus and extensor digitorum longus (EDL) muscles were incubated with or without 2 mU of insulin per ml. 2-Deoxyglucose uptake in insulin-stimulated muscles was then measured for 20 min as described previously (33).
Western blotting. Soleus and EDL muscles were pulverized in liquid nitrogen, homogenized, and lysed as described previously (35), and 2x Laemmli sample buffer containing 7.5% ß-mercaptoethanol was added to 30 µg of lysate. The samples were heated for 15 min at 65°C, resolved by sodium dodecyl sulfate-10% polyacrylamide gel electrophoresis (SDS-10% PAGE), and then immunoblotted with polyclonal anti-phospho-Akt (Thr308) and pan-Akt antibodies (1:1,000 dilution of primary antibodies; Cell Signaling Technology, Beverly, Mass.).
Immunohistochemistry and PAS staining. Pancreatic tissue was fixed overnight in a solution of freshly prepared 4% paraformaldehyde in 0.1 M phosphate-buffered saline (pH 7.4) at 4°C. Samples were dehydrated and prepared as paraffin blocks. Seven-micrometer-thick sections of paraffin-embedded pancreatic tissue were stained with hematoxylin and eosin for histological examination. For periodic acid-Schiff (PAS) staining, slides were preheated for 5 min with 1% periodic acid in mQ-water followed by a wash step for 1 min in tap water, followed by a wash dip for 5 s in mQ-water. The slides then were treated with Schiff's reagent (Sigma) for 15 min at room temperature.
Statistical analysis. All groups of data for 2-deoxyglucose uptake results and Western blots for total and phospho Akt were compared by using one-way analysis of variance (ANOVA) followed by Tukey or Newman-Keuls post hoc tests with the statistical software program GraphPad Prism.
| RESULTS |
|---|
|
|
|---|
|
|
Insulin-stimulated glucose uptake into soleus muscle is improved in mckPten/ mice fed a high-fat diet. To assess whether the enhanced insulin sensitivity in the mckPten/ mice on a high-fat diet is the result of higher glucose uptake into muscle, we measured basal and insulin-stimulated 2-deoxyglucose uptake into isolated soleus muscles of 6-month-old mckPten+/+ and mckPten/ mice fed a high-fat or chow diets. When fed normal chow, mckPten+/+ and mckPten/ mice had similar levels of basal (mckPten+/+, 7.3 ± 1.2 pmol/mg of muscle/20 min; mckPten/, 5.3 ± 0.4 pmol/mg of muscle/20 min [P = NS]) and insulin-stimulated (mckPten+/+, 13.1 ± 1.4 pmol/mg of muscle/20 min; mckPten/, 11.6 ± 1.6 pmol/mg of muscle/20 min [P = NS]) 2-deoxyglucose uptake into soleus muscle (Fig. 3A). When fed a high-fat diet, mckPten+/+ and mckPten/ mice had similar levels of basal 2-deoxyglucose uptake into soleus muscle (mckPten+/+, 2.2 ± 1.1 pmol/mg of muscle/20 min; mckPten/, 1.9 ± 1.0 pmol/mg of muscle/20 min)). However, insulin-stimulated 2-deoxyglucose uptake was significantly elevated in soleus muscles of mckPten/ mice (4.0 ± 1.7 pmol/mg of muscle/20 min) compared to their wild-type littermates (3.1 ± 1.6 pmol/mg of muscle/20 min) (P < 0.05 by ANOVA) (Fig. 3B). In contrast, both basal (mckPten+/+, 1.69 ± 0.84 pmol/mg of muscle/20 min; mckPten/, 2.03 ± 0.87 pmol/mg of muscle/20 min [P = NS]) and insulin-stimulated (mckPten+/+, 2.49 ± 1.26 pmol/mg of muscle/20 min; mckPten/, 2.35 ± 1.09 pmol/mg of muscle/20 min [P = NS]) glucose uptake into EDL muscle was not significantly different in high-fat-fed mckPten+/+ and mckPten/ mice (Fig. 3C). These results suggest that the improved glucose homeostasis observed in mckPten/mice on a high-fat diet may be the result of increased insulin-stimulated glucose uptake primarily into slow-twitch oxidative fibers.
|
|
|
The body weights of older mckPten/ mice fed a normal chow or high-fat diet did not differ from those of mckPten+/ littermates (data not shown). Similarly after a high-fat diet, the epididymal fat mass was similar in mckPten+/ (3.3 ± 0.6 g) and mckPten/ (3.4 ± 0.9 g) mice (P = 0.97) at 15 months of age. Despite the parallel gain in body weight and fat mass, mckPten/ mice remained consistently more insulin sensitive than mckPten+/ mice on a prolonged high-fat diet, as measured by the insulin tolerance test (Fig. 6A). Furthermore, these older mckPten/ mice fed a high-fat diet had lower glucose levels upon glucose challenge (Fig. 6B). In addition, the prolonged protective metabolic effect in mckPten/ mice continued without gross or histologic development of tumors.
|
|
Protection from hyperinsulinemia and ß-cell hypertrophy. In order to prevent the progression of insulin resistance to overt diabetes, the capacity of pancreatic ß cells to mount a hyperinsulinemic response to meet the increased demand for insulin is crucial. Typically, insulin resistance elicits hypertrophy or hyperplasia of ß cells and increased serum insulin levels. We therefore examined whether ß-cell compensation is alleviated in the more insulin-sensitive mckPten/ mice when they are given a high-fat diet. Fasting insulin levels in the sera of 6-month-old mckPten/ and mckPten+/+ mice fed a normal chow and a high-fat diet were measured. In keeping with the notion that preserved insulin sensitivity would spare mckPten/ mice from mounting a hyperinsulinemic response, a higher proportion of the mckPten/ mice had lower fasting plasma insulin levels than control littermates (Fig. 8A).
|
These results show that Pten deletion in muscle protects against the proliferative demand on the ß cells as a consequence of enhanced insulin sensitivity. This proliferative demand is an additional contributing factor to disease progression in type 2 diabetes. Pten deletion in muscle gave protection against insulin resistance and diabetes without development of muscle tumors or other deleterious effects in the high-fat and age-induced diabetes model.
| DISCUSSION |
|---|
|
|
|---|
In both age groups of high-fat-fed mice, muscle-specific deletion of Pten preserved insulin-stimulated glucose uptake in slow-twitch, oxidative soleus muscle but not in fast-twitch EDL muscle (Fig. 3 and 5). Similarly, insulin-stimulated Akt phosphorylation was enhanced in soleus but not EDL muscles from mckPten/ mice compared to heterozygous littermates. The distinct responses might reflect the differences in fiber type composition of the two muscle types: mouse soleus muscle has a much higher content of slow-twitch, oxidative type I fibers (approximately 40 to 50%) (45), whereas mouse EDL muscle is composed mainly of fast-twitch, glycolytic type IIB fibers (36). Moreover, slow-twitch, oxidative fibers are more insulin sensitive and show higher insulin-stimulated glucose uptake than fast-twitch, glycolytic muscle fibers (25, 50). Muscles composed mainly of type I fibers are more susceptible to high-fat-feeding-induced insulin resistance than type 2 fiber-containing muscles (50; D. Konrad and A. Klip, unpublished observations). Thus, one could argue that high-fat feeding and aging affect mainly soleus muscle and not EDL muscle, and therefore, only deletion of Pten in the insulin-resistant muscle had a compensatory effect. Consistent with this tenet, insulin-stimulated PI3K activity is reduced in soleus but not in EDL muscles in high-fat-fed mice (50). In mckPten/ mice, this defect is rescued by the absence of Pten, presumably by improved glucose uptake into oxidative muscle. Interestingly, a recent study reemphasizes the importance of reduced mitochondrial oxidative capacity in the pathogenesis of insulin resistance in elderly people (32). We report here the occurrence of insulin resistance mainly in the more oxidative soleus muscle and not in the glycolytic EDL muscle.
Even though skeletal muscle plays an important role in glucose homeostasis under physiological conditions (11), its functional contribution to insulin resistance and type 2 diabetes was recently questioned by the finding that muscle-specific deletion of the insulin receptor did not result in whole-body insulin resistance and diabetes (4). Possible explanations offered included insulin signaling via the insulin-like growth factor-1 receptor and glucose uptake by non-insulin-dependent pathways (22). On the other hand, insulin resistance in skeletal muscle is a consistent finding in type 2 diabetes patients (25). Moreover, several studies report the occurrence of insulin resistance in skeletal muscle as an early event in the development of type 2 diabetes mellitus (47). Our findings further support the concept that alterations in skeletal muscle play at least a permissive role in the development of type 2 diabetes.
It is well documented that insulin sensitivity declines with age, and several factors have been implicated in this decline (28). Here, we show that deletion of muscle Pten gives prolonged protection against insulin resistance and diabetes even in aged mice fed a prolonged high-fat diet, without the deleterious effects often expected with Pten inactivation. This result highlights the ability of Pten to potently regulate different cellular processes in a highly context-dependent manner, tailoring regulatory effects to different cell types. In muscle, a major function of Pten appears to be metabolic regulation of insulin action. In keeping with these results, polymorphism in the 5'-untranslated region of the Pten gene has been found in a diabetic cohort in Japan. This polymorphism was associated with an increased expression level of Pten and decreased phosphorylation of Akt upon stimulation with insulin in an experimental cell line model (16).
Negative regulators of insulin signaling are attractive targets for the development of new therapeutic approaches to treat insulin resistance and diabetes mellitus. PTP-1B directly interacts with and dephosphorylates activated insulin receptors. PTP-1B knockout mice are protected from obesity and insulin resistance, possibly through enhancing effects on leptin signaling in liver (7, 49). Lipid phosphatase SHIP2 has also been shown to modulate insulin action. SHIP2 deletion leads to increased insulin sensitivity associated with severe perinatal hypoglycemia and death, whereas adult mice heterozygous for the SHIP2 mutation have better glucose tolerance and insulin sensitivity (9). However, in these genetic models, it is unclear which insulin target organs contribute primarily to diabetes protection. Since these genetic models were whole-body knockouts, the specific contribution of each insulin-sensitive organ to whole-body glucose control could not be assessed. We show here that amelioration of insulin signaling in skeletal muscle via deletion of Pten in muscle is able to improve the control of whole-body glucose.
Selective Pten deletion in skeletal muscle protects against the development of fat- and age-dependent insulin resistance and diabetes without the development of cancer. Here we show that deletion of Pten in muscle affects metabolism without affecting other facets of Pten physiology that have been shown to be important in other tissues, such as hypertrophy or proliferation. We thus show the exquisite specificity of Pten for tissue type and show mckPten/ mice to be a good model to study the effect of muscle insulin signaling in insulin resistance. Pten in muscle is a promising therapeutic target to overcome insulin resistance and ameliorate glucose homeostasis in type 2 diabetes.
| ACKNOWLEDGMENTS |
|---|
We thank Paul Dogherty, Armen Manoukian, Stephanie Backman, and Kinh Tung Nguyen for critical editing of the manuscript and helpful discussions. We also thank Xudong Xhu, Kelvin So, and Michelle Sleiman for their technical assistance. We thank Lifescan Johnson and Johnson for providing glucometer strips.
| FOOTNOTES |
|---|
N.W., D.K., and M.E. contributed equally towards this work. ![]()
Present address: Division of Endocrinology and Diabetology, University Children's Hospital, Zurich, Switzerland. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Backman, S. A., D. Ghazarian, K. So, O. Sanchez, K. U. Wagner, L. Hennighausen, A. Suzuki, M. S. Tsao, W. B. Chapman, V. Stambolic, and T. W. Mak. 2004. Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of Pten. Proc. Natl. Acad. Sci. USA 101:1725-1730.
3. Backman, S. A., V. Stambolic, A. Suzuki, J. Haight, A. Elia, J. Pretorius, M. S. Tsao, P. Shannon, B. Bolon, G. O. Ivy, and T. W. Mak. 2001. Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat. Genet. 29:396-403.[CrossRef][Medline]
4. Bruning, J. C., M. D. Michael, J. N. Winnay, T. Hayashi, D. Horsch, D. Accili, L. J. Goodyear, and C. R. Kahn. 1998. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2:559-569.[CrossRef][Medline]
5. Butler, M., R. A. McKay, I. J. Popoff, W. A. Gaarde, D. Witchell, S. F. Murray, N. M. Dean, S. Bhanot, and B. P. Monia. 2002. Specific inhibition of Pten expression reverses hyperglycemia in diabetic mice. Diabetes 51:1028-1034.
6. Cheatham, B., C. J. Vlahos, L. Cheatham, L. Wang, J. Blenis, and C. R. Kahn. 1994. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell. Biol. 14:4902-4911.
7. Cheng, A., N. Uetani, P. D. Simoncic, V. P. Chaubey, A. Lee-Loy, C. J. McGlade, B. P. Kennedy, and M. L. Tremblay. 2002. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2:497-503.[CrossRef][Medline]
8. Cho, H., J. Mu, J. K. Kim, J. L. Thorvaldsen, Q. Chu, E. B. Crenshaw III, K. H. Kaestner, M. S. Bartolomei, G. I. Shulman, and M. J. Birnbaum. 2001. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292:1728-1731.
9. Clement, S., U. Krause, F. Desmedt, J. F. Tanti, J. Behrends, X. Pesesse, T. Sasaki, J. Penninger, M. Doherty, W. Malaisse, J. E. Dumont, Y. Le Marchand-Brustel, C. Erneux, L. Hue, and S. Schurmans. 2001. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409:92-97.[CrossRef][Medline]
10. Crackower, M. A., G. Y. Oudit, I. Kozieradzki, R. Sarao, H. Sun, T. Sasaki, E. Hirsch, A. Suzuki, T. Shioi, J. Irie-Sasaki, R. Sah, H. Y. Cheng, V. O. Rybin, G. Lembo, L. Fratta, A. J. Oliveira-dos-Santos, J. L. Benovic, C. R. Kahn, S. Izumo, S. F. Steinberg, M. P. Wymann, P. H. Backx, and J. M. Penninger. 2002. Regulation of myocardial contractility and cell size by distinct PI3K-Pten signaling pathways. Cell 110:737-749.[CrossRef][Medline]
11. DeFronzo, R. A., R. Gunnarsson, O. Bjorkman, M. Olsson, and J. Wahren. 1985. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin-dependent (type II) diabetes mellitus. J. Clin. Investig. 76:149-155.
12. Fink, R. I., P. Wallace, and J. M. Olefsky. 1986. Effects of aging on glucose-mediated glucose disposal and glucose transport. J. Clin. Investig. 77:2034-2041.
13. Gil, E. B., E. Malone Link, L. X. Liu, C. D. Johnson, and J. A. Lees. 1999. Regulation of the insulin-like developmental pathway of Caenorhabditis elegans by a homolog of the Pten tumor suppressor gene. Proc. Natl. Acad. Sci. USA 96:2925-2930.
14. Hara, K., K. Yonezawa, H. Sakaue, A. Ando, K. Kotani, T. Kitamura, Y. Kitamura, H. Ueda, L. Stephens, T. R. Jackson, et al. 1994. 1-Phosphatidylinositol 3-kinase activity is required for insulin-stimulated glucose transport but not for RAS activation in CHO cells. Proc. Natl. Acad. Sci. USA 91:7415-7419.
15. Horie, Y., A. Suzuki, E. Kataoka, T. Sasaki, K. Hamada, J. Sasaki, K. Mizuno, G. Hasegawa, H. Kishimoto, M. Iizuka, M. Naito, K. Enomoto, S. Watanabe, T. W. Mak, and T. Nakano. 2004. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Investig. 113:1774-1783.[CrossRef][Medline]
16. Ishihara, H., T. Sasaoka, S. Kagawa, S. Murakami, K. Fukui, Y. Kawagishi, K. Yamazaki, A. Sato, M. Iwata, M. Urakaze, M. Ishiki, T. Wada, S. Yaguchi, H. Tsuneki, I. Kimura, and M. Kobayashi. 2003. Association of the polymorphisms in the 5'-untranslated region of Pten gene with type 2 diabetes in a Japanese population. FEBS Lett. 554:450-454.[CrossRef][Medline]
17. Jiang, Z. Y., Q. L. Zhou, K. A. Coleman, M. Chouinard, Q. Boese, and M. P. Czech. 2003. Insulin signaling through Akt/protein kinase B analyzed by small interfering RNA-mediated gene silencing. Proc. Natl. Acad. Sci. USA 100:7569-7574.
18. Kahn, C. R. 2003. Knockout mice challenge our concepts of glucose homeostasis and the pathogenesis of diabetes. Exp. Diabesity Res. 4:169-182.[Medline]
19. Katagiri, H., T. Asano, H. Ishihara, K. Inukai, Y. Shibasaki, M. Kikuchi, Y. Yazaki, and Y. Oka. 1996. Overexpression of catalytic subunit p110alpha of phosphatidylinositol 3-kinase increases glucose transport activity with translocation of glucose transporters in 3T3-L1 adipocytes. J. Biol. Chem. 271:16987-16990.
20. Katome, T., T. Obata, R. Matsushima, N. Masuyama, L. C. Cantley, Y. Gotoh, K. Kishi, H. Shiota, and Y. Ebina. 2003. Use of RNA interference-mediated gene silencing and adenoviral overexpression to elucidate the roles of AKT/protein kinase B isoforms in insulin actions. J. Biol. Chem. 278:28312-28323.
21. Kishimoto, H., K. Hamada, M. Saunders, S. Backman, T. Sasaki, T. Nakano, T. W. Mak, and A. Suzuki. 2003. Physiological functions of Pten in mouse tissues. Cell Struct. Funct. 28:11-21.[CrossRef][Medline]
22. Kitamura, T., C. R. Kahn, and D. Accili. 2003. Insulin receptor knockout mice. Annu. Rev. Physiol. 65:313-332.[CrossRef][Medline]
23. Kruszynska, Y. T., and J. M. Olefsky. 1996. Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J. Investig. Med. 44:413-428.[Medline]
24. Li, J., C. Yen, D. Liaw, K. Podsypanina, S. Bose, S. I. Wang, J. Puc, C. Miliaresis, L. Rodgers, R. McCombie, S. H. Bigner, B. C. Giovanella, M. Ittmann, B. Tycko, H. Hibshoosh, M. H. Wigler, and R. Parsons. 1997. Pten, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
25. Lillioja, S., A. A. Young, C. L. Culter, J. L. Ivy, W. G. Abbott, J. K. Zawadzki, H. Yki-Jarvinen, L. Christin, T. W. Secomb, and C. Bogardus. 1987. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J. Clin. Investig. 80:415-424.
26. Mauvais-Jarvis, F., R. N. Kulkarni, and C. R. Kahn. 2002. Knockout models are useful tools to dissect the pathophysiology and genetics of insulin resistance. Clin. Endocrinol. 57:1-9.[CrossRef][Medline]
27. Mihaylova, V. T., C. Z. Borland, L. Manjarrez, M. J. Stern, and H. Sun. 1999. The Pten tumor suppressor homolog in Caenorhabditis elegans regulates longevity and dauer formation in an insulin receptor-like signaling pathway. Proc. Natl. Acad. Sci. USA 96:7427-7432.
28. Miles, P. D., Y. Barak, R. M. Evans, and J. M. Olefsky. 2003. Effect of heterozygous PPARgamma deficiency and TZD treatment on insulin resistance associated with age and high-fat feeding. Am. J. Physiol. Endocrinol. Metab. 284:E618-E626.
29. Nakashima, N., P. M. Sharma, T. Imamura, R. Bookstein, and J. M. Olefsky. 2000. The tumor suppressor Pten negatively regulates insulin signaling in 3T3-L1 adipocytes. J. Biol. Chem. 275:12889-12895.
30. Ogg, S., and G. Ruvkun. 1998. The C. elegans Pten homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell 2:887-893.[CrossRef][Medline]
31. Ono, H., H. Katagiri, M. Funaki, M. Anai, K. Inukai, Y. Fukushima, H. Sakoda, T. Ogihara, Y. Onishi, M. Fujishiro, M. Kikuchi, Y. Oka, and T. Asano. 2001. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by Pten (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol. Endocrinol. 15:1411-1422.
32. Petersen, K. F., D. Befroy, S. Dufour, J. Dziura, C. Ariyan, D. L. Rothman, L. DiPietro, G. W. Cline, and G. I. Shulman. 2003. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140-1142.
33. Rudich, A., D. Konrad, D. Torok, R. Ben-Romano, C. Huang, W. Niu, R. R. Garg, N. Wijesekara, R. J. Germinario, P. J. Bilan, and A. Klip. 2003. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. Diabetologia 46:649-658.[Medline]
34. Scheid, M. P., and J. R. Woodgett. 2001. PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell. Biol. 2:760-768.[CrossRef][Medline]
35. Somwar, R., M. Perreault, S. Kapur, C. Taha, G. Sweeney, T. Ramlal, D. Y. Kim, J. Keen, C. H. Cote, A. Klip, and A. Marette. 2000. Activation of p38 mitogen-activated protein kinase alpha and beta by insulin and contraction in rat skeletal muscle: potential role in the stimulation of glucose transport. Diabetes 49:1794-1800.[Abstract]
36. Song, X. M., J. W. Ryder, Y. Kawano, A. V. Chibalin, A. Krook, and J. R. Zierath. 1999. Muscle fiber type specificity in insulin signal transduction. Am. J. Physiol. 277:R1690-R1696.
37. Stambolic, V., A. Suzuki, J. L. de la Pompa, G. M. Brothers, C. Mirtsos, T. Sasaki, J. Ruland, J. M. Penninger, D. P. Siderovski, and T. W. Mak. 1998. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor Pten. Cell 95:29-39.[CrossRef][Medline]
38. Stambolic, V., M. S. Tsao, D. Macpherson, A. Suzuki, W. B. Chapman, and T. W. Mak. 2000. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/ mice. Cancer Res. 60:3605-3611.
39. Steck, P. A., M. A. Pershouse, S. A. Jasser, W. K. Yung, H. Lin, A. H. Ligon, L. A. Langford, M. L. Baumgard, T. Hattier, T. Davis, C. Frye, R. Hu, B. Swedlund, D. H. Teng, and S. V. Tavtigian. 1997. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:356-362.[CrossRef][Medline]
40. Stiles, B., Y. Wang, A. Stahl, S. Bassilian, W. P. Lee, Y. J. Kim, R. Sherwin, S. Devaskar, R. Lesche, M. A. Magnuson, and H. Wu. 2004. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity. Proc. Natl. Acad. Sci. USA 101:2082-2087. (Erratum, 101:5180.)
41. Suzuki, A., J. L. de la Pompa, V. Stambolic, A. J. Elia, T. Sasaki, I. del Barco Barrantes, A. Ho, A. Wakeham, A. Itie, W. Khoo, M. Fukumoto, and T. W. Mak. 1998. High cancer susceptibility and embryonic lethality associated with mutation of the Pten tumor suppressor gene in mice. Curr. Biol. 8:1169-1178.[CrossRef][Medline]
42. Suzuki, A., S. Itami, M. Ohishi, K. Hamada, T. Inoue, N. Komazawa, H. Senoo, T. Sasaki, J. Takeda, M. Manabe, T. W. Mak, and T. Nakano. 2003. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res. 63:674-681.
43. Suzuki, A., T. Kaisho, M. Ohishi, M. Tsukio-Yamaguchi, T. Tsubata, P. A. Koni, T. Sasaki, T. W. Mak, and T. Nakano. 2003. Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J. Exp. Med. 197:657-667.
44. Tanti, J. F., T. Gremeaux, S. Grillo, V. Calleja, A. Klippel, L. T. Williams, E. Van Obberghen, and Y. Le Marchand-Brustel. 1996. Overexpression of a constitutively active form of phosphatidylinositol 3-kinase is sufficient to promote Glut 4 translocation in adipocytes. J. Biol. Chem. 271:25227-25232.
45. Totsuka, Y., Y. Nagao, T. Horii, H. Yonekawa, H. Imai, H. Hatta, Y. Izaike, T. Tokunaga, and Y. Atomi. 2003. Physical performance and soleus muscle fiber composition in wild-derived and laboratory inbred mouse strains. J. Appl. Physiol. 95:720-727.
46. Tsakiridis, T., M. Vranic, and A. Klip. 1994. Disassembly of the actin network inhibits insulin-dependent stimulation of glucose transport and prevents recruitment of glucose transporters to the plasma membrane. J. Biol. Chem. 269:29934-29942.
47. Vaag, A., J. E. Henriksen, and H. Beck-Nielsen. 1992. Decreased insulin activation of glycogen synthase in skeletal muscles in young nonobese Caucasian first-degree relatives of patients with non-insulin-dependent diabetes mellitus. J. Clin. Investig. 89:782-788.
48. Wang, Q., R. Somwar, P. J. Bilan, Z. Liu, J. Jin, J. R. Woodgett, and A. Klip. 1999. Protein kinase B/Akt participates in GLUT4 translocation by insulin in L6 myoblasts. Mol. Cell. Biol. 19:4008-4018.
49. Zabolotny, J. M., K. K. Bence-Hanulec, A. Stricker-Krongrad, F. Haj, Y. Wang, Y. Minokoshi, Y. B. Kim, J. K. Elmquist, L. A. Tartaglia, B. B. Kahn, and B. G. Neel. 2002. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2:489-495.[CrossRef][Medline]
50. Zierath, J. R., K. L. Houseknecht, L. Gnudi, and B. B. Kahn. 1997. High-fat feeding impairs insulin-stimulated GLUT4 recruitment via an early insulin-signaling defect. Diabetes 46:215-223.[Abstract]
51. Zisman, A., O. D. Peroni, E. D. Abel, M. D. Michael, F. Mauvais-Jarvis, B. B. Lowell, J. F. Wojtaszewski, M. F. Hirshman, A. Virkamaki, L. J. Goodyear, C. R. Kahn, and B. B. Kahn. 2000. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 6:924-928.[CrossRef][Medline]
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||